Discussion
TPST-4003, Tempest Therapeutics’ next-generation CAR T-cell therapy for autoimmune diseases such as myasthenia gravis (MG), will soon be tested in people for the first time, the developer announced. The upcoming investigator-initiated clinical trial, to…